PEP-Therapy Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 5
Employees
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $6.41M
Latest Deal Amount
  • Investors
  • 11

PEP-Therapy General Information

Description

Developer of innovative peptides designed to offer targeted therapies for severe diseases, with an initial focus on oncology. The company's peptides are active compounds that penetrate cells and block relevant intracellular protein interactions that offer intracellular delivery of targeted therapies, enabling healthcare providers to get inhibiting key pathological mechanisms.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Drug Discovery
Primary Office
  • Pépinière Genopole Entreprises
  • 4 rue Pierre Fontaine
  • 91058 Evry Cedex
  • France
+33 01 00 00 00 00

PEP-Therapy Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

PEP-Therapy Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series A) 19-Jul-2021 $6.41M 000.00 Completed Clinical Trials - General
6. Grant 22-Apr-2021 00.000 00.000 Completed Clinical Trials - General
5. Later Stage VC 31-Oct-2020 00.000 00.000 00.000 Completed Generating Revenue
4. Early Stage VC 16-Nov-2017 00.00 00.000 00.000 Completed Pre-Clinical Trials
3. Early Stage VC 00000 00.000 Completed Pre-Clinical Trials
2. Grant 01-Jan-2016 $1.4M Completed Pre-Clinical Trials
1. Seed Round 27-Apr-2015 $1.4M $1.4M 00.000 Completed Pre-Clinical Trials
To view PEP-Therapy’s complete valuation and funding history, request access »

PEP-Therapy Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
P shares 0,000 00.000000 0000.00 0000.00 00 0000.00 0.000
P shares 0,000 00.000000 000.00 000.00 00 000.00 00.000
Preference 11,250 $1.176860 $125.54 $125.54 1x $125.54 14.56%
Ordinary 19,500 $1.176860 $78.46 $78.46 1x $78.46 25.25%
To view PEP-Therapy’s complete cap table history, request access »

PEP-Therapy Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of innovative peptides designed to offer targeted therapies for severe diseases, with an initial focus on onco
Biotechnology
Evry Cedex, France
5 As of 2021
000.00
00000000000 000.00

00000000

ommodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fu
0000000000000
Berlin, Germany
0 As of 0000
000.00
00000000000 000.00

0000000

abore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nis
0000000000000
Louisville, KY
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

PEP-Therapy Competitors (27)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Eternygen Venture Capital-Backed Berlin, Germany 0 000.00 00000000000 000.00
0000000 0000000000 Formerly VC-backed Louisville, KY 00 00000 00000000 00000
0000000 0000000000 Venture Capital-Backed Cambridge, MA 000 00000 00000000000 00000
000000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 0000000000 0 00000
00000 00000000000 Formerly VC-backed Cambridge, MA 00 00000 000000000 00000
You’re viewing 5 of 27 competitors. Get the full list »

PEP-Therapy Executive Team (5)

Name Title Board Seat Contact Info
Antoine Prestat Co-Founder, Chief Executive Officer & Board Member
Fariba Némati Ph.D Scientific Co-Founder and Scientific Advisor
Angelita Rebollo Ph.D Scientific Co-Founder & Scientific Advisor
Didier Decaudin Ph.D Scientific Co-Founder & Scientific Advisor
You’re viewing 4 of 5 executive team members. Get the full list »

PEP-Therapy Board Members (5)

Name Representing Role Since
Antoine Prestat PEP-Therapy Co-Founder, Chief Executive Officer & Board Member 000 0000
Bernard Majoie Ph.D Self Board Member 000 0000
Jean-Loup Romet-Lemonne MD Self Board Member 000 0000
Michele Marzola Ph.D Italian Angels for Growth Board Member 000 0000
Philippe Tramoy Seventure Partners Board Member 000 0000
To view PEP-Therapy’s complete board members history, request access »

PEP-Therapy Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PEP-Therapy Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
ANAXAGO Real Estate Minority 000 0000 000000 0
Doorway Capital Corporation Minority 000 0000 000000 0
i&i Prague Venture Capital Minority 000 0000 000000 0
Italian Angels for Growth Angel Group Minority 000 0000 000000 0
Les Business Angels des Grandes Écoles Angel Group Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »